Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20815511 | 0.95 | ALDH1A1 (0.56) | CYP17A1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28251750 | 0.93 | ALDH1A1 (0.54) | CYP17A1ALDH1A1NPC1RAB9APDK1 | |
| SCHEMBL7076030 | 0.91 | NPC1 (0.68) | CYP17A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL13055402 | 0.90 | CYP17A1 (0.59) | CYP17A1ALDH1A1SMN1; SMN2PSMB8NAMPT | |
| SCHEMBL12387210 | 0.87 | PDK1 (0.55) | CYP17A1ALDH1A1NPC1RAB9APDK1 | |
| SCHEMBL12387203 | 0.85 | PDK1 (0.50) | CYP17A1NPC1RAB9APDK1PDK2 | |
| SCHEMBL23619661 | 0.85 | SMN1; SMN2 (0.62) | CYP17A1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20865536 | 0.85 | CYP17A1 (0.68) | CYP17A1SMN1; SMN2PSMB8NAMPTL3MBTL1 | |
| SCHEMBL23484531 | 0.84 | CA12 (0.47) | CYP17A1ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL19853161 | 0.84 | PDK1 (0.51) | ALDH1A1NPC1RAB9APDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108794519-B | A kind of oxygen bridge containing boric acid deriveding group is bicyclic-[2.2.1]-heptan vinyl compound, its synthetic method and application | 武汉大学 | 2019-11-08 | — | — | CN | claimed |
| US-20260132137-A1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1-[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYSTALLINE FORMS THEREOF | HOFFMANN LA ROCHE INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12459947-B2 | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crystalline forms thereof | HOFFMANN-LA ROCHE INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12433896-B2 | Deuterated analogs of etifoxine, their derivatives and uses thereof | GABA THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| WO-2024092039-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2024-04-11 | — | — | US | disclosed |
| US-6348616-B1 | CHEMICAL INTERMEDIATES FOR SYNTHESIS OF DESIRED BENZOXAZINONES | PIERCE MICHAEL ERNEST (US) | 2002-02-19 | — | — | US | disclosed |
| WO-2000069836-A1 | SHORT-ACTING BENZODIAZEPINES | GLAXO GROUP LIMITED (GB) | 2000-11-23 | — | — | WO | disclosed |
| US-6147210-A | Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-11-14 | — | — | US | disclosed |
| WO-1998004535-A1 | A PRACTICAL SYNTHESIS OF BENZOXAZINONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0081877-B1 | LH-RH ANTAGONISTS | COY, David Howard (US) | 1986-04-30 | — | — | EP | disclosed |
| EP-0065864-B1 | ANTI-HYPERTENSIVE 1-SUBSTITUTED SPIRO (PIPERIDINE-OXOBENZOXAZINES) | SYNTEX (U.S.A.) INC. (US) | 1985-08-28 | — | — | EP | disclosed |
| EP-0041286-B1 | LH-RH ANTAGONISTS | Schally, Andrew Victor (US) | 1984-08-15 | — | — | EP | disclosed |
| EP-0081877-A1 | LH-RH antagonists | COY, David Howard (US) | 1983-06-22 | — | — | EP | disclosed |
| EP-0065864-A1 | Anti-hypertensive 1-substituted spiro (piperidine-oxobenzoxazines) | SYNTEX (U.S.A.) INC. (US) | 1982-12-01 | — | — | EP | disclosed |
| US-4349549-A | Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s | SYNTEX (U.S.A.) INC. (US) | 1982-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | CYP17A1 4403/4885ALDH1A1 3991/4885NPC1 526/4885 |
| US-12433896-B2 | Deuterated analogs of etifoxine, their derivatives and uses thereof | CYP2F1, CYP3A5, CYP4F3 | CYP17A1 190/4885ALDH1A1 1324/4885NPC1 3181/4885 |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | CYP17A1 4403/4885ALDH1A1 3991/4885NPC1 526/4885 |
| US-20260132137-A1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1-[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYSTALLINE FORMS THEREOF | YWHAQ, CCT8, CYP2C18 | CYP17A1 429/4885ALDH1A1 4208/4885NPC1 3436/4885 |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | CYP17A1 4403/4885ALDH1A1 3991/4885NPC1 526/4885 |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | CYP17A1 3289/4885ALDH1A1 3818/4885NPC1 3502/4885 |
| US-12459947-B2 | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crystalline forms thereof | NT5C, CYP8B1, AZI2 | CYP17A1 248/4885ALDH1A1 473/4885NPC1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.